Combination cancer immunotherapy and new immunomodulatory targets

@article{Mahoney2015CombinationCI,
  title={Combination cancer immunotherapy and new immunomodulatory targets},
  author={Kathleen M. Mahoney and Paul D. Rennert and Gordon J. Freeman},
  journal={Nature Reviews Drug Discovery},
  year={2015},
  volume={14},
  pages={561-584}
}
Targeting immune checkpoints such as programmed cell death protein 1 (PD1), programmed cell death 1 ligand 1 (PDL1) and cytotoxic T lymphocyte antigen 4 (CTLA4) has achieved noteworthy benefit in multiple cancers by blocking immunoinhibitory signals and enabling patients to produce an effective antitumour response. Inhibitors of CTLA4, PD1 or PDL1 administered as single agents have resulted in durable tumour regression in some patients, and combinations of PD1 and CTLA4 inhibitors may enhance… 

Figures and Tables from this paper

Combination cancer immunotherapies tailored to the tumour microenvironment
TLDR
The stratification of the tumours microenvironment according to tumour-infiltrating lymphocytes and PD-L1 expression in the tumour is discussed, and how this stratification enables the design of optimal combination cancer therapies tailored to target different tumour microenvironments.
Immune Checkpoints as a Target for Colorectal Cancer Treatment
TLDR
An updated review of the biological background and clinical development of immune checkpoint inhibitors in colorectal cancer (CRC) is presented and early trial results on PD1 and PD-L1 blockade appear promising, especially in CRC patients with microsatellite instability.
Immuno-Oncology: Emerging Targets and Combination Therapies
TLDR
The breadth and quality of immunotherapeutic approaches and the types of cancers that can be treated will increase significantly in the foreseeable future.
Advances of Immune Checkpoint Inhibitors in Tumor Immunotherapy
TLDR
In this review, the recent advances of the study and development of the checkpoint molecules CTLA-4 and PD-1 and other checkpoint molecules in tumor immunotherapy are summarized.
Safety of combining radiotherapy with immune-checkpoint inhibition
TLDR
Data from numerous retrospective series and a handful of prospective studies provide burgeoning evidence that the combination of palliative radiotherapy and ICI is safe overall without a substantial site-specific increase in adverse events.
PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
TLDR
The current landscape of the PD-1/PD-L1 mechanistic role in tumor immune evasion and therapeutic outcome for cancer treatment is reviewed and the current progress in clinical trials, combination of drug therapy with immunotherapy, safety, and future of check point inhibitors for multiple types of cancer are reviewed.
Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications
TLDR
The mechanisms of action of these immunostimulatory mAbs, conceived to activate co-stimulatory receptors on immune effector cells, are discussed and recent progress in their preclinical and clinical development is summarized.
Cancer immunotherapy by targeting immune checkpoints: mechanism of T cell dysfunction in cancer immunity and new therapeutic targets
  • H. Tsai, P. Hsu
  • Biology, Medicine
    Journal of Biomedical Science
  • 2017
TLDR
Recent advance(s) in molecular understanding of T cell dysfunction in tumor microenvironments are reviewed and new immune checkpoint targets in cancer therapy are discussed.
Biomarkers of response to PD-1/PD-L1 inhibition.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 298 REFERENCES
Checkpoint Blockade Cancer Immunotherapy Targets Tumour-Specific Mutant Antigens
TLDR
Tumour-specific mutant proteins are identified as a major class of T-cell rejection antigens following anti-PD-1 and/or anti-CTLA-4 therapy of mice bearing progressively growing sarcomas, and it is shown that therapeutic synthetic long-peptide vaccines incorporating these mutant epitopes induce tumour rejection comparably to checkpoint blockade immunotherapy.
Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape.
TLDR
A strong synergy between the PD-1 and LAG-3 inhibitory pathways in tolerance to both self and tumor antigens is defined and it is argued strongly that dual blockade of these molecules represents a promising combinatorial strategy for cancer.
The blockade of immune checkpoints in cancer immunotherapy
  • D. Pardoll
  • Biology, Medicine
    Nature Reviews Cancer
  • 2012
TLDR
Preliminary clinical findings with blockers of additional immune-checkpoint proteins, such as programmed cell death protein 1 (PD1), indicate broad and diverse opportunities to enhance antitumour immunity with the potential to produce durable clinical responses.
PD-1 Blockade and OX40 Triggering Synergistically Protects against Tumor Growth in a Murine Model of Ovarian Cancer
TLDR
Combined anti-PD-1 or OX40 mAb treatment markedly inhibited tumor outgrowth with 60% of mice tumor free 90 days after tumor inoculation, and provides a rationale for clinical trials evaluating ovarian cancer immunotherapy using this combination of mAb.
PD-1 blockade induces responses by inhibiting adaptive immune resistance
TLDR
It is shown that pre-existing CD8+ T cells distinctly located at the invasive tumour margin are associated with expression of the PD-1/PD-L1 immune inhibitory axis and may predict response to therapy.
Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy
TLDR
The immune response to tumors is summarized, preclinical and early clinical data on select TNFR family members are considered, potential translational challenges are discussed and possible combination therapies with the aim of inducing durable antitumor responses are suggested.
Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs
TLDR
Combined anti-PD-1/GITR mAb treatment induces a potent antitumor immunity, which can be further promoted by chemotherapeutic drugs and should be considered translation into clinic.
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
TLDR
It is found that T cell immunoglobulin mucin (Tim) 3 is expressed on CD8+ tumor-infiltrating lymphocytes (TILs) in mice bearing solid tumors and combined targeting of the Tim-3 and PD-1 pathways is more effective in controlling tumor growth than targeting either pathway alone.
OX40 is a potent immune-stimulating target in late-stage cancer patients.
TLDR
The findings clinically validate OX40 as a potent immune-stimulating target for treatment in patients with cancer, providing a generalizable tool to favorably influence the antitumor properties of circulating T cells, B cells, and intratumoral regulatory T cells.
...
1
2
3
4
5
...